Novo Nordisk, goodrx sells ozemPic at a half cost to customers who pay the money
Novo Nordisk and GOODRX announced this week to sell OzemPic and Wegov products with half of its regular cost to patients who pay for medicines in cash.
Starting this week, customers will be able to purchase a month of Novo Nordis products for $ 499 through Goodrx. The price of the monthly supply menu of a product such as OzemPIC is usually about $ 1,000 or more without insurance.
“The demand for GLP-1 drugs at the highest level ever, but many Americans are still facing the barriers of access to it,” said Glodrx CEO and President Windy Barnes in a statement.
“Through partnership with Novo Nordisk, we are taking a big step forward in making these innovative brand treatments easier for millions of people who need them,” Barnes added. “It is a strong example of how the Goodrx platform provides widespread savings – gags in coverage and ensure that more people can get the care they deserve.”
This is the latest in the similar movements by Novo Nordisk to make the famous diabetes and weight loss medications available on a wider scale.
Earlier this year, the company announced a direct program to a patient called Novocare Pharmacy for unbelievable and non -insured individuals who can pay $ 499 per month to Wegovy. Novo Nordisk has also made a partnership with a distance online health care companies such as RO and Lifem to sell their pens at the same point.
HIMS & HERS HIMS & HERS was also included in the partnership, but Novo Nordisk ended it after the illegal sale company of selling the vehicle was accused of Semaglutide. HIMS & HERS maintains it provides custom and vehicle products within organizational guidelines.
“Improving access to effective treatment approved by the FDA is essential in our mission, and our cooperation with Goodrx allows us to access those looking for savings and support from a reliable and proven platform,” said Dave Moore, CEO of Novo Nordisk, in a statement.
“This initiative enables us to meet GODRX patients where they are with the original GLP-1 medicines in addition to supporting the launch of the new self-wage offer for type 2 diabetics at an unprecedented price.”
Senator Bernie Sanders (I-VT), a prominent critic of high drug costs, described the announcement as a “modest step forward.”
Sanders said on the social platform X: “The Novo Nordisk step to reduce the price of OzemPic to $ 499 for the benefit of the insured, but let’s not forget,” Sanders said on the social platform X.
